Epigenomics AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPGNF research report →
About the company
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The company was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo G.
- CEO
- Jason Wouhra
- IPO
- 2010
- Employees
- 3
- HQ
- Heidelberg, DE
Price Chart
- Market Cap
- $982.21K
- P/E
- -0.05
- P/S
- 1.26
- P/B
- 0.28
- EV/EBITDA
- 0.76
- Div Yield
- 0.00%
- Gross Margin
- 75.26%
- Op Margin
- -2484.74%
- Net Margin
- -2479.18%
- ROE
- -74.47%
- ROIC
- -107.86%
- Revenue
- $23.99K · 0.00%
- Net Income
- $-313,882 · 90.63%
- EPS
- $-0.36 · 90.58%
- Op Income
- $-335,873
- FCF YoY
- 0.00%
- 52W High
- $1.12
- 52W Low
- $0.79
- 50D MA
- $1.12
- 200D MA
- $1.03
- Beta
- 0.85
- Avg Volume
- 555.887
Get TickerSpark's AI analysis on EPGNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our EPGNF coverage
Recent articles, reports, and earnings notes.
No research on EPGNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EPGNF report →Similar companies
Peers in the same neighborhood.